glur2

Primidone (NCI-C56360) is a potent anticonvulsant agent. It is a neuronal voltage-gated sodium channel blocker and has value in the study of epilepsy, essential tremor, and psychiatric disorders.

Pep2-EVKI acetate is a cell-permeable peptide. Pep2-EVKI acetate interferes the interaction between protein interacting with C-kinase (PICK1) and GluR2 AMPA receptor subunits.

mGluR2 modulator5 (Compound 11) is a selective negative allosteric modulator with oral activity, exhibiting an IC50 of 8.9 nM. Pharmacokinetic studies in rats have demonstrated its effective penetration through the blood-brain barrier. This compound is utilized in research related to cognitive and neurological functions in mood disorders, contributing to the field of neurological diseases.

mGluR2 agonist1 hydrochloride is a potent and selective agonist of the metabotropic glutamate receptor (mGluR2), with an EC50 of 82 nM.

mGluR2 agonist1 (Compound 5b) is a potent and selective metabotropic glutamate receptor 2 (mGluR) agonist with an EC50 of 82 nM. It is applicable for research in central nervous system (CNS) disorders.

mGluR2 modulator6 (Compound 25-a) acts as an mGluR2 modulator demonstrating anticonvulsant activity in the 6Hz epilepsy model, with enhanced effects when used in combination with Levetiracetam. This compound is valuable for epilepsy research.

mGluR2 antagonist 1 is a potent and selective class of negative allosteric modulator targeting the metabotropic glutamate receptor 2 (mGluR2) with high oral bioavailability. It displays a remarkable affinity for mGluR2, with an IC50 value of 9 nM. Furthermore, it exhibits excellent permeability across the blood-brain barrier, making it a promising candidate for central nervous system-related studies or therapies.

mGluR2 modulator 2 (compound 2) is a potent, selective, and orally bioavailable positive allosteric modulator of mGluR2 with an EC50 value of 0.13 μM [1], and can be used in antipsychotic research.

4 (compound 47) is a highly potent positive allosteric modulator of mGluR2, exhibiting an EC50 value of 0.8 μM, with potential for investigating antipsychotic properties [1].

mGluR2 modulator 1 (compound 95) is a potent, blood-brain-barrier permeable modulator of mGluR2 (metabotropic glutamate receptor-2) with an EC50 of 0.03 μM. mGluR2 modulator 1 can be used in the study of psychiatric disorders.

TAT-GluR23A Fusion Peptide is a bioactive peptide comprising the GluR23A sequence—residues 869 to 877 of GluR23Y with alanine replacing tyrosine—and an 11 amino acid cell-permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). It serves as an inactive control counterpart to the glutamate receptor endocytosis inhibitor GluR23Y, devoid of crucial phosphorylation sites.

GluR23Y, a biologically active peptide, was utilized in an ELISA-based cell-surface assay to assess insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y effectively inhibited the insulin-induced decrease in receptor presence. The inhibition of insulin effects was achieved by introducing GluR23Y into neurons through fusion with the membrane transduction domain of HIV-1 TAT.

EGLU ((2S)-α-Ethylglutamic acid) is a competitive mGluR-2 receptor antagonist with antidepressant activity and anti-injury effects, which can be used in the study of arthritis.

3-MATIDA is an effective mGluR-1 antagonist (IC50: 6.3 μM, rat mGluR-1a). Displays ≥ 40-fold selectivity over other receptors: mGluR-5, mGluR-2, mGluR-4 (mGluR-4a) (IC50 > 300 μM), NMDA and GluR (AMPA) (IC50 = 250 μM). 3-MATIDA act as a neuroprotectant in cultured murine cortical cells and rat hippocampal slice cultures in vitro.

MNI 137 is a negative allosteric modulator of mGlu2. MNI 137 inhibits glutamate-induced calcium mobilization with IC50s of 8.3 and 12.6 nM for human and rat.

JNJ-42153605 is a mGlu2 receptor positive allosteric modulator (EC50: 17 nM).

AZD-8529 is a highly selective, and orally bioavailable positive allosteric modulator of mGluR2 (EC50: 285 nM). It shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

AZD-8529 mesylate is a highly selective, and orally bioavailable positive allosteric modulator of mGluR2 (EC50: 285 nM). It shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

DCG-IV is an effective agonist of class II mGluR. DCG-IV has anticonvulsant and neuroprotective effects. The EC50 of mGlu2R and mGlu3R are 0.35 and 0.09 μM, respectively. DCG-IV is also a competitive antagonist of Group I (IC50: mGlu1 / 5R = 389/630 μM) a

L-Cysteinesulfinic acid is an endogenous neurotransmitter with agonistic effects on a variety of metabotropic glutamate receptors (mGluRs), including mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, with a pEC50 = 2.7 to 4.0. L- Cysteinesulfinic acid is a pld-coupled agonist of metabotropic excitatory amino acid (EAA) receptors.

LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively.LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells.

LY2140023 has the potential for schizophrenia.LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist.

LY3020371 hydrochloride exerts an antidepressant-like signature in vivo. LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM.

Biphenylindanone A is a selective potentiator of human mGluR2 (hmGluR2),and for the treatment of neurological disorders.